Daré Bioscience Secures Significant Funding for Women's Health Initiatives
Daré Bioscience, Inc. (NASDAQ: DARE), renowned for its commitment to enhancing women’s health, has announced a pivotal $15 million common stock purchase agreement with Lincoln Park Capital Fund, LLC, a prominent institutional investor. This agreement aims to bolster Daré's development of innovative products tailored for women's health and wellbeing.
Details of the Stock Purchase Agreement
This strategic agreement allows Daré to sell up to $15 million worth of its common stock to LPC over the next 24 months. The execution of this deal is contingent upon the filing and approval of a registration statement by the SEC, which will enable LPC to resell the shares purchased under this agreement. Importantly, Daré retains the authority to dictate when and how much stock it sells, providing the company with valuable control over its capital-raising efforts.
How This Funding Supports Daré's Development Programs
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, expressed excitement about this collaboration with LPC. She noted that the funding from a prior arrangement in 2020 significantly contributed to the development of XACIATO, Daré's FDA-approved vaginal gel. Johnson emphasized that similar funding could facilitate the advancement of multiple investigational products, particularly Sildenafil Cream, 3.6%. This innovative treatment is poised to be a first-in-category solution for female sexual arousal disorder, a trail Daré is navigating with ongoing discussions with the FDA regarding the design of its pivotal Phase 3 clinical trial.
Understanding the Conditions of the Agreement
As outlined in the purchase agreement, LPC commits to refraining from any actions such as short selling or hedging involving Daré’s common stock. The agreement is highly favorable, allowing Daré to use proceeds without restrictions and without incurring additional costs if they decide to terminate the agreement at their discretion.
About Daré Bioscience
Daré Bioscience is dedicated to pioneering products that address a wide array of women’s health issues, focusing on areas such as contraception, vaginal health, reproductive health, and menopause. With a diverse portfolio, the company aims to improve health outcomes and expand treatment options for women globally.
Innovative Product Portfolio
The company has introduced XACIATO, the first FDA-approved product for treating bacterial vaginosis in women. This product is pivotal in Daré’s ongoing mission to advance women's health and is marketed under a global license agreement with Organon. Furthermore, Daré is developing several other promising candidates, like Ovaprene, a hormone-free contraceptive, and DARE-HRT1, an advanced therapy for menopausal women.
Recognition and Leadership
Daré's leadership has received accolades within the pharmaceutical community, being recognized for its commitment to innovation and advocacy for women’s health. The CEO was honored in 2023 among the most influential figures in biopharma, showcasing Daré’s commitment to driving change in this crucial area of healthcare.
Frequently Asked Questions
What is the purpose of the agreement with Lincoln Park Capital?
The agreement allows Daré to raise up to $15 million to support the development of its women's health product portfolio without the immediate need for traditional equity financing.
What products are part of Daré’s pipeline?
Daré’s portfolio includes initiatives like Sildenafil Cream for female sexual arousal disorder and Ovaprene, a novel contraceptive method.
How does the funding impact Daré's research programs?
The funding will provide Daré the necessary capital to conduct clinical trials, such as the Phase 3 study for Sildenafil Cream, essential for progressing their product development.
What is XACIATO?
XACIATO is an FDA-approved vaginal gel for treating bacterial vaginosis, marking a significant entry for Daré in the women's health market.
How has Daré been recognized in the industry?
Daré has received accolades including top rankings in the San Diego Business Journal’s Best Places to Work Awards and recognition for its impactful leadership.
